PopPK Modeling of Rivoceranib in Healthy Subjects and Patients with Cancer

• Recipients of “Top Poster Ribbon” in “Recognition of high-quality abstract”
  
  

This poster focuses on the pharmacokinetic study of Rivoceranib in both healthy subjects and patients with various types of cancers. By collecting and analyzing data from different populations (e.g. cancer patients, healthy individuals, etc.), a kinetic model of drug absorption, distribution, metabolism and excretion in the human body was developed. The study revealed that different disease types can impact the pharmacokinetic properties of drugs. For instance, drug clearance is reduced in liver cancer patients, while bioavailability is decreased in gastric cancer patients. These findings are crucial for the development of tailored treatment plans.